{"name":"Medivir","slug":"medivir","ticker":"MVIR.ST","exchange":"Nasdaq Stockholm","domain":"medivir.com","description":"Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. \nMedivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.\nMedivir is listed on the Nasdaq Stockholm Mid Cap List.","hq":"Stockholm, Sweden","founded":0,"employees":"10","ceo":"Jens Lindberg","sector":"Oncology / Hepatology","stockPrice":2.48,"stockChange":0.2,"stockChangePercent":8.77,"marketCap":"$1.3B","metrics":{"revenue":8500000,"revenueGrowth":522.2,"grossMargin":0,"rdSpend":0,"netIncome":-94400000,"cash":119200000,"dividendYield":0,"peRatio":-2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"MIV-818 patent cliff ($0.0B at risk)","drug":"MIV-818","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"ME-609 patent cliff ($0.0B at risk)","drug":"ME-609","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ME-609","genericName":"ME-609","slug":"me-609","indication":"Chronic hepatitis C virus infection","status":"phase_3"},{"name":"acyclovir in ME-609 vehicle","genericName":"acyclovir in ME-609 vehicle","slug":"acyclovir-in-me-609-vehicle","indication":"Herpes simplex virus infections","status":"phase_3"}]}],"pipeline":[{"name":"ME-609","genericName":"ME-609","slug":"me-609","phase":"phase_3","mechanism":"ME-609 is a hepatitis C virus (HCV) NS5B polymerase inhibitor that blocks viral RNA replication.","indications":["Chronic hepatitis C virus infection"],"catalyst":""},{"name":"acyclovir in ME-609 vehicle","genericName":"acyclovir in ME-609 vehicle","slug":"acyclovir-in-me-609-vehicle","phase":"phase_3","mechanism":"Acyclovir is an antiviral medication that inhibits viral DNA synthesis by inhibiting viral DNA polymerase.","indications":["Herpes simplex virus infections","Varicella-zoster virus infections","Herpes zoster"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Medivir reports Q4 2023 results","summary":"Medivir reported its Q4 2023 financial results, with revenue of SEK 14.1 million and a net loss of SEK 123.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Medivir enters into a collaboration agreement with a leading pharmaceutical company","summary":"Medivir entered into a collaboration agreement with a leading pharmaceutical company to develop and commercialize MIV-818 in combination with pembrolizumab.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"trial","headline":"Medivir announces positive interim results from the ME-609 phase 3 trial","summary":"Medivir announced positive interim results from the ME-609 phase 3 trial, showing significant improvements in patient outcomes.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPRWdUWXB2bk82bnk4QThOLUV0eFpQcDJuZ2s3QWZlZGlVX0lzcElWeDhaYUk4SEJqOGFZblZBR1dtbHdIRG9hUGx0OVdjdzZMUVZxOXQtaTFsZFZpdllkM1NlRGZsYXZFbjUtTFh4clIydFh1UUlVSS1sYUd3amJSd0lHNEpCdnlDdEZqcEtJVWNSVVdySWJfYzVqM19iX0hSTnVLOGVOTFJmMGNxb2daeVByMGdGVVpQbUZld3NHckJHUDJ1aXQ4SlBNejZVbVRHdFYwRmR1RmktN1Rpa0NMZHNiSQ?oc=5","date":"2026-03-04","type":"trial","source":"The Globe and Mail","summary":"Medivir Names New CFO to Steer Next Phase of Strategic Transformation - The Globe and Mail","headline":"Medivir Names New CFO to Steer Next Phase of Strategic Transformation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQUEY4WWZvX1hDZkpJT09ORDB2LXg3YnBRdmFKbFFWeUlMdXZUOTNLVVNhNHI5YTB5dzRnZWVHYVFTaVdqZFhQekx6VTk0UUJDTzZ0QlNlMjhySm42VG5XY1NISzROSHJUMF9QSmF1Ukk2cWEzRm9BTExibUVBN2lYbFd0REpiZ1NDVDNJMzdUQS15OExjYkZnVlN4QkdEY2x4WkxiNkpVcjNGVUxS?oc=5","date":"2026-03-02","type":"pipeline","source":"TradingView","summary":"Medivir recruits Patrik Norgren as new CFO - TradingView","headline":"Medivir recruits Patrik Norgren as new CFO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1Na0J2LWc0b2R2aDExZGpZUm5RbDRIV1BIeWhoc3pzcTBkbUp6dENVR0ZVbzc4bFhRLVJnaTVFdlRqMjBhUjF3Tnh0dHV1cXAzUXkteldjVnZxX0dz?oc=5","date":"2024-02-24","type":"pipeline","source":"TradingView","summary":"MVIR Stock Price and Chart — OMXSTO:MVIR - TradingView","headline":"MVIR Stock Price and Chart — OMXSTO:MVIR","sentiment":"neutral"}],"patents":[{"drugName":"MIV-818","drugSlug":"fostroxacitabine-bralpamide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"ME-609","drugSlug":"acyclovir-in-me-609-vehicle","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Gilead Sciences","Merck & Co."],"therapeuticFocus":["Oncology","Hepatology"],"financials":null,"yahoo":{"currentPrice":2.48,"previousClose":2.28,"fiftyTwoWeekHigh":2.88,"fiftyTwoWeekLow":0.34,"fiftyTwoWeekRange":"0.34 - 2.885","fiftyDayAverage":1.57,"twoHundredDayAverage":1.24,"beta":0.24,"enterpriseValue":911970368,"forwardPE":-2,"priceToBook":4.2,"priceToSales":157.17,"enterpriseToRevenue":107.29,"enterpriseToEbitda":-15.07,"pegRatio":0,"ebitda":-60500000,"ebitdaMargin":0,"freeCashflow":-39340000,"operatingCashflow":-73300000,"totalDebt":8200000,"debtToEquity":3.1,"currentRatio":3.66,"returnOnAssets":-24.3,"returnOnEquity":-49.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":5.43,"targetHighPrice":6.86,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":831600000,"insiderHeldPercent":42.3,"institutionHeldPercent":8.3,"sharesOutstanding":538671220,"floatShares":246715330,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.66,"epsForward":-1.23,"revenuePerShare":0.06,"bookValue":0.59,"officers":[{"age":54,"name":"Mr. Jens  Lindberg","title":"Chief Executive Officer"},{"age":62,"name":"Mr. Patrik  Norgren","title":"Chief Financial Officer"},{"age":60,"name":"Mr. Fredrik  Öberg","title":"Chief Scientific Officer"},{"age":59,"name":"Ms. Pia  Baumann","title":"Chief Medical Officer"},{"age":null,"name":"Karin  Tunblad","title":"Senior Principal Scientist & MIV-818 Project Leader"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.medivir.com","phone":"46 8 54 68 31 00"}}